Navigation Links
Study finds 'rescue course' of antenatal steroids improves outcome in premature babies
Date:1/29/2009

WASHINGTON, DC In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, researchers will unveil findings that show that premature babies born before 34 weeks have a 31 percent reduction in serious complications when given a "rescue course" of Antenatal Corticosteroids (ACS) steroids with no adverse side effects noted.

"Premature babies are very susceptible to respiratory problems which may lead to additional severe complications," said Dr. James Kurtzman, M.D. (Associate Professor, UC Irvine Medical Center). "Antenatal steroids clearly reduce the risk of these respiratory complications."

Years ago doctors gave multiple courses of antenatal steroids to mothers who were at risk for delivering prematurely. However, certain studies found that there were possible adverse affects to multiple ACS courses because babies were found to have slightly smaller head circumferences and lower birth weights. As a result the National Institutes of Health (NIH) recommended further study.

"The effect (of the NIH recommendation) was that doctors were only giving one ACS course, and they were nervous about when to give it for the best effect. They often waited until the last minute, and some women didn't get a complete treatment or didn't get it at all," said Dr. Kurtzman. "What this study has found is that we can give women who threaten to deliver prematurely an initial ACS course, and if they remain pregnant, we can give one 'rescue course' closer to delivery. By doing so, the babies' complications are reduced by about a third with no adverse side effects found."

In this study, which took place over five years in 18 different medical centers and was supported by the Pediatrix Medical Group, 437 patients were randomized (233 in the study group, and 214 in the placebo group). The results showed a significant reduction in composite neonatal morbidity for babies born prior to 34 weeks in the "rescue steroid" group vs. placebo (43.9% vs. 63.6%) as well as significant decrease in respiratory distress syndrome, ventilator support, and surfactant use. When all neonates were included in the analysis (regardless of the gestational age at delivery), a significant reduction in composite morbidity in the "rescue steroid" group was still demonstrated (32.1% vs. 42.6%).


'/>"/>

Contact: Vicki Bendure
vicki@bendurepr.com
202-374-9259
Society for Maternal-Fetal Medicine
Source:Eurekalert

Related biology news :

1. Brain structure assists in immune response, according to Penn vet study
2. Study finds MRSA in Midwestern swine, workers
3. New study provides further evidence that apple juice can delay onset of Alzheimers disease
4. UD research study to shed light on emerging seaborne pathogen
5. Study links water pollution with declining male fertility
6. UGA study may give hope that ivory-billed woodpeckers still around
7. Evolutionary process more detailed than previously believed, study shows
8. Researchers to use K-States BSL-3 Lab for $1 million study of fungus threatening wheat crops
9. Human beta cells can be easily induced to replicate, according to study in Diabetes
10. Primate culture is just a stones throw away from human evolution, study finds
11. Disabling enzyme allows mice to gorge without becoming obese, new study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... Shinyaku, Co., Ltd. for Defitelio ® (defibrotide sodium) ... or CPX-351, in Japan . ... will receive exclusive rights to develop and commercialize Defitelio ... return for an upfront payment to Jazz Pharmaceuticals and ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Crohn’s & Colitis ... inflammatory bowel diseases (IBD), and ReachMD , the nation’s largest medical education ... learners. , The partnership, which launched in the fall of 2016, includes ...
(Date:3/29/2017)... 29, 2017 "Surging application of gesture control ... government are expected to drive the growth of gesture ... recognition market is expected to be worth USD 18.98 ... between 2017 and 2022. The touchless sensing market is ... growing at a CAGR of 17.44% between 2017 and ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... announce that Nerium International Mexico has been approved as an active member of ... achieve satisfaction and protection among distributers and consumers in relationship marketing. This professional ...
Breaking Biology Technology: